David A. Roth
2017 - Syros Pharmaceuticals
In 2017, David A. Roth earned a total compensation of $1.1M as Chief Medical Officer at Syros Pharmaceuticals, a 117% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $172,000 |
|---|---|
| Option Awards | $504,418 |
| Salary | $400,000 |
| Other | $270 |
| Total | $1,076,688 |
Roth received $504.4K in option awards, accounting for 47% of the total pay in 2017.
Roth also received $172K in non-equity incentive plan, $400K in salary and $270 in other compensation.
Rankings
In 2017, David A. Roth's compensation ranked 8,634th out of 14,666 executives tracked by ExecPay. In other words, Roth earned more than 41.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,634 out of 14,666 | 41st |
Division Manufacturing | 3,280 out of 5,768 | 43rd |
Major group Chemicals And Allied Products | 1,103 out of 2,074 | 47th |
Industry group Drugs | 875 out of 1,730 | 49th |
Industry Pharmaceutical Preparations | 683 out of 1,329 | 49th |
Source: SEC filing on April 26, 2018.
Roth's colleagues
We found two more compensation records of executives who worked with David A. Roth at Syros Pharmaceuticals in 2017.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019